[Skip to Content]
[Skip to Content Landing]
July 18, 1990

A Call About Erythropoietin: Conflict of Interest or Investment Opportunity?-Reply

Author Affiliations

Branch Manager Shearson Lehman Hutton Tampa, Fla

Branch Manager Shearson Lehman Hutton Tampa, Fla

JAMA. 1990;264(3):334. doi:10.1001/jama.1990.03450030050016

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


In Reply.—  I'm sorry if there was any misunderstanding about the nature of the call my colleague made to Dr Morris. The call was intended specifically to discuss investment opportunities in the biotechnology industry.Our equity research analysts who follow the pharmaceutical and biotechnology industries are among the most highly regarded in the securities industry. Shearson believes that there are many companies that represent attractive investment opportunities in these areas, particularly those distributing erythropoietin.Shearson Lehman Hutton is not aware of any restrictions that preclude physicians from investing in pharmaceutical companies while they prescribe those companies' products.